Affirm Holdings, Inc. Announces Pricing of Upsized Private Offering of $800 million of 0.75% Convertible Senior Notes due 2029
SAN FRANCISCO--(BUSINESS WIRE)--Affirm Holdings, Inc. (Nasdaq: AFRM) (“Affirm” or the “Company”) today…
Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination
December 16, 2024 16:30 ET | Source: Bannix Acquisition Corp. WILMINGTON, Del.,…
NETCLASS TECHNOLOGY INC. Announces Closing of $9 Million Initial Public Offering
December 16, 2024 16:15 ET | Source: NETCLASS TECHNOLOGY INC. SHANGHAI and…
Merus Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing…
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq:…
GENESIS UNVEILS REDESIGNED ELECTRIFIED GV70
First-ever redesign of Electrified GV70 introduces sophisticated exterior and interior upgradesKorean sales…
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq:…
Presidio Announces Human-Centric AI Accelerators to Drive Strategic Outcomes
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Presidio, a leading technology…
MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds…
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Novel H2CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on…